Catalyst Pharma to Acquire New Product

TL;DR

Catalyst Pharma buying a new drug, closing Q4 2024.

AI Summary

Catalyst Pharmaceuticals, Inc. announced on September 24, 2024, that it has entered into a definitive agreement to acquire a pharmaceutical product from a third party. The acquisition is expected to close in the fourth quarter of 2024. This strategic move aims to expand Catalyst's product portfolio and leverage its existing commercial infrastructure.

Why It Matters

This acquisition could significantly expand Catalyst Pharmaceuticals' product offerings, potentially leading to increased revenue and market share in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, regulatory hurdles, and the possibility that the acquired product may not perform as expected financially.

Key Players & Entities

• Catalyst Pharmaceuticals, Inc. (company) — Registrant
• September 24, 2024 (date) — Date of earliest event reported
• fourth quarter of 2024 (date) — Expected closing of acquisition

FAQ

From the Filing

0001193125-24-226538.txt : 20240926 0001193125-24-226538.hdr.sgml : 20240926 20240926084228 ACCESSION NUMBER: 0001193125-24-226538 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240924 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240926 DATE AS OF CHANGE: 20240926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 241326250 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d841208d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-09-24 2024-09-24     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 24, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle Suite 801 Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On September 24, 2024, the Company issued a press release announcing that its sub-licensee in Japan, DyDo Pharma, Inc. (“ DyDo ”), has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo’s New Drug Application (“ NDA ”) to commercialize FIRDAPSE ® (amifampridine) Tablets 10 mg for the treatment of patients wit